A recent study demonstrated that the DPP-4 inhibitor linagliptin alleviates hepatic steatosis and inflammation in a new murine model of NASH with a diabetic background independently of its glucose-lowering effect [5]. This evidence concerns the gene DPP4 and Hepatic steatosis.